RITT yields 2000000.00% · ABBV yields 3.06%● Live data
📍 RITT pulled ahead of the other in Year 1
Combined, RITT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RITT + ABBV for your $10,000?
RiT Technologies Ltd. provides intelligent infrastructure management (IIM) and indoor optical wireless technology solutions worldwide. The company's IIM products enhance security and network utilization for data centers, communication rooms, and work space environments. Its enterprise solutions include PatchView hardware, which is offered in a cross connect topology; CenterMind data center management software that supports the monitoring of power distribution units, and environmental parameters in data centers; and SMART Cabling System, a structured network infrastructure solution designed for copper and fiber cabling environments. It also offers Beamcaster, an indoor wireless optical solution that allows high-speed, high-bandwidth transmission through optical signals between the central station and the user station. The company's solutions are deployed in a range of organizations, including data centers in the private sector, government agencies, financial institutions, airport authorities, healthcare, and education institutions. RiT Technologies Ltd. markets its products through independent distributors, resellers/integrators, original equipment manufacturers, and other strategic alliance partners with companies. The company was founded in 1989 and is headquartered in Tel Aviv, Israel. RiT Technologies Ltd. operates as a subsidiary of Stins Coman Incorporated.
Full RITT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.